Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives new EU approval for Fluenz Tetra

AstraZeneca receives new EU approval for Fluenz Tetra

6th December 2013

AstraZeneca has announced that its influenza vaccine Fluenz Tetra has been approved in Europe.

The European Commission has ratified the vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age. It is the first intranasal four-strain influenza vaccine available in the EU.

Data from a pivotal paediatric study showed that Fluenz Tetra offers a comparable safety and immunogenicity profile to Fluenz, the company's three-strain live attenuated influenza vaccine, which has already been approved in Europe.

The older therapy protected against two influenza A viruses (H1N1 and H3N2) and one influenza B virus, but the new vaccine offers additional protection against a second influenza B strain.

Filip Dubovsky, vice-president of clinical biologics, infectious disease and vaccines at AstraZeneca's biologics arm MedImmune, said: "Fluenz Tetra represents the next generation of influenza vaccine and we are pleased that it is now approved in Europe."

This comes after AstraZeneca announced last month that it will be building a new manufacturing facility in Macclesfield, as well as appointing an architect for its new global research and development centre and corporate headquarters in Cambridge.ADNFCR-8000103-ID-801669571-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.